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Asthma is a complex syndrome with many clinical phenotypes in children and adults. Despite the rapidly increasing prevalence, clinical 
investigation and epidemiological studies of asthma, the successful introduction of new drugs has been limited due to the different disease 
phenotypes and ethical issues. Mouse models of asthma replicate many of the features of human asthma, including airway hyperreactivity, and 
airway inflammation. Therefore, examination of disease mechanisms in mice has been used to elucidate asthma pathology and to identify and 
evaluate new therapeutic agents. In this article, we discuss the various animal models of asthma with a focus on mouse strains, allergens, 
protocols, and outcome measurements.
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INTRODUCTION
The prevalence of allergic airway disease is rapidly increasing 
world-wide in all age groups; in recent decades, the prevalence 
in children is reportedly over 30% in many countries and great-
er than 10% in some adult populations.
1,2 Although under-
standing of the pathogenesis of the disease has progressed 
enormously in the last several decades, the development and 
addition of new therapeutic agents in asthma has been very 
limited. The mainstay of therapy remains inhaled corticoste-
roids, which although impacting the disease in significant ways, 
does not address all issues and in all patients.
3
Asthma is a complex syndrome with many clinical pheno-
types. Common to all is chronic inflammation with reversible 
airway obstruction and airway hyperresponsiveness (AHR).
4 
The most prevalent form of asthma is atopic asthma which is 
initiated by the exposure to (inhaled) allergens and resultant al-
lergen-specific immune responses. Indeed, early sensitization 
to allergen, by 3 yr of age, may be an important predictor for 
persistent wheezing 10 yr later.
5,6 As we are all exposed to the 
same inhaled allergens, the genetic regulation of these respons-
es is an important component in defining susceptible individu-
als. In addition to allergen exposure, other exposure risk factors 
such as viral infection, occupational exposure, air pollution, 
and environmental tobacco smoke are important contributors 
to the different phenotypes of asthma and asthma heterogene-
ity.
7-10 Similar to other diseases, clinical investigation and epide-
miological studies are essential for the advancement of knowl-
edge and disease management. However, the ability to 
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comprehensively assess the different disease phenotypes and 
inherent ethical issues are limiting factors in conducting many 
of the required clinical studies. As a result, animal models have 
been developed to study the pathogenesis of the disease, in-
cluding genetic factors, to define the pathogenetic pathways 
and suggest new therapeutic approaches.
11,12 That being said, it 
is clear that the results in animal studies are not easily translat-
ed to humans and therapeutic initiatives successful in animals 
have generally been of limited success in the clinic. This has 
prompted debate about the utility of animal models.
13
ANIMALS 
Animal models of asthma have been extensively used to ex-
amine mechanisms of disease, the activity of a variety of genes 
and cellular pathways, and to predict the safety of new drugs or 
chemicals before being used in clinical studies.
12 Advances in 
the understanding of the pathophysiology of asthma as an al-
lergic airway disease would not have been possible without 
these models. Although asthma was associated with airway eo-
sinophilia for more than a century, the contributors to this 
characteristic cellular inflammatory response followed on the 
descriptions of T helper cell functional heterogeneity and the 
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distinct cytokine profiles described initially in mice. Indeed, 
most of the mechanisms of disease that are discussed today de-
rive from the studies conducted in animal models.
14 
There is a wide variety of animal models of asthma in different 
species. Mice, rats, guinea pigs, ferrets, dogs, sheep, monkeys 
and horses have been employed to study the inflammatory 
processes and alterations in airway function.
15-19 Each animal 
possesses certain advantages and disadvantages as a model of 
allergic airway disease (Table 1).
Mouse models of allergic airway disease offer numerous ad-
vantages when compared to the use of other animals. IgE is the 
primary allergic antibody in mice, making this species appro-
priate for investigation of the role of humoral immune factors 
in the development of allergic airway disease. Further, mouse 
models offer the opportunity to explore detailed mechanisms 
of allergic reactions because of the availability of numerous im-
munological reagents such as antibodies against cytokines, 
growth factors, and cell surface markers. Numerous well-char-
acterized inbred strains of mice are available, which allow di-
rect transfer of cells between the same strain of animals for the 
assessment of function of specific factors and cells. In addition, 
the emerging technologies involving gene manipulation in ani-
mals is well-advanced in mice. The ease of breeding and short 
gestational period is an additional advantage. Accordingly, ma-
jor advances in the understanding of the disease concept, 
“asthma as Th2-dominant disease” , emerged from studies in 
mice. 
On the other hand, because of considerable physiologic dif-
ferences between mice and humans, extrapolation of findings 
to humans needs to be judicious. To a large extent these differ-
ences explain many of the failures to translate findings in the 
mouse to the clinic. Among these differences is the anatomy 
and differentiation and branching of the airways, the vascula-
ture, and the somewhat limited airway musculature. Mice do 
not exhibit spontaneous AHR and smooth muscle hyperplasia 
is not easily demonstrated. The mice fail to develop airway con-
strictive responses to histamine and for studies of neurogenic 
inflammation, it is difficult to detect non-adrenergic/non-cho-
linergic (NANC) activated or inhibitory responses. A major lim-
iting factor in mice and in virtually all animal models is the ab-
sence of a truly chronic model, a model where challenges are 
experienced over many months to years, akin to the human 
asthmatic. 
Although a majority of studies of allergic airway disease are 
now carried out in the mouse, the guinea pig initially was uti-
lized as an animal model of pulmonary hypersensitivity and 
AHR for many decades.
20 The guinea pig demonstrated airway 
constrictive responses, hyperreactivity towards cholinergic ago-
nists, and production of hypersensitivity antibodies, including 
IgG1 and IgE.
21 The major benefit of the guinea pig was the abil-
ity to target the lung as the primary target organ of a hypersen-
sitivity response. Further, both immediate- and late-phase air-
way responses following allergen challenge readily developed 
in this species, allowing mechanistic investigation of the dis-
tinct phases of altered airway function, as well as determining 
the interplay between the early- and late-phase responses. The 
associated pulmonary inflammatory response is consistent 
with asthma, composed of both eosinophils and neutrophils. 
The guinea pig model identified the importance of airway in-
flammation in the development of altered airway function.
21 
However, there are several disadvantages in using guinea pigs 
as a model of asthma. The shortage of inbred strains prevents 
Table 1. Advantages and disadvantages of individual animal models of asthma
Animal Advantage Disadvantage
Mouse IgE is the primary anaphylactic antibody
Numerous immunological reagents
Numerous inbred strains
Easy breeding
Short gestational period
Small and relatively inexpensive
Do not exhibit spontaneous airway hyperresponsiveness
Limited airway musculature
Lung anatomical differences 
Do not respond to histamine
Absence of a chronic model
Rat IgE is the primary anaphylactic antibody
Produce long-lasting airway response
Show immediate and late phase airway responses
Requires injection of the allergen for sensitization
Requires adjuvants for sensitization
Species-specific immunological reagents are not abundant
Guinea pig Lung is the primary target of anaphylaxis
Response to cholinergic agonists
Show immediate and late phase airway responses
Pulmonary inflammation composed of eosinophils and neutrophils
IgG1 is the major anaphylactic antibody 
Shortage of inbred strains
Few species-specific reagents 
Rabbit Show immediate and late phase airway responses
Lung is the primary target of anaphylaxis
IgE is the primary anaphylactic antibody
Neonatal immunization required for late phase airway response
Large animals Horses naturally develop respiratory disorders when exposed to barn dust
Monkeys develop natural sensitivity to Ascaris
Hard to handle 
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meaningful investigation of the genetic influences on suscepti-
bility to sensitization and development of allergic airway dis-
ease. In addition, few species-specific reagents exist, making it 
difficult to identify and isolate particular cell types. Another 
major disadvantage to the guinea pig is the predominance of 
IgG1 rather than IgE as the major anaphylactic antibody.
21 
The rat, another small rodent, has been used by numerous in-
vestigators. The production of IgE as the major anaphylactic 
antibody enables the study of the control of the synthesis of al-
lergen-specific antibodies, as well as the role of this antibody in 
the physiological and cellular responses to allergen. Another 
benefit is the ability to produce long-lasting airway hyperreac-
tivity. Both immediate- and late-phase airway responses fol-
lowing allergen challenge have been produced in strains of rats, 
however, sensitization typically requires injection of the aller-
gen, rather than administration via the inhalation route as is 
used with guinea pigs.
22,23 In addition, allergic sensitization, as 
in the mouse, requires use of adjuvants, specifically alum or 
Bordetella pertussis.
24 Species-specific immunological reagents 
are not as abundant as they are in mice. These are major limita-
tions for the study of allergic airway responses. 
The rabbit provides an animal model which resembles hu-
mans in that the lung is the target organ for anaphylactic re-
sponses. This species can demonstrate both immediate- and 
late-phase airway responses, has vigorous NANC responses 
and IgE is the primary anaphylactic antibody. 
 Larger animals such as monkeys, sheep, and horses have been 
used in asthma models. However, they are hard to handle and 
too expensive to use on a regular basis. Horses are the only ani-
mals which naturally develop respiratory disorders character-
ized by acute airway obstruction when exposed to barn dust.
25 
Monkeys may develop natural airway sensitivity to Ascaris.
26 
In light of the predominant use of mice as surrogates, this re-
view article focuses on mouse models. In considering the use of 
mice, several distinct components need to be considered, the 
genetic background of the mice, the allergen, the experimental 
approach, and the outcome measures. The interplay between 
these four components is exceptionally complex and under-
standing the biological implications is essential to the extrapo-
lation to human disease.
STRAINS OF MICE 
The availability of various inbred mouse strains is an advan-
tage, but problems can arise if an inappropriate mouse strain is 
selected. The ability to induce parameters of allergic airway in-
flammation and AHR varies greatly among the different strains 
with both responders and non-responders. A/J and AKR/J mice 
display high levels of allergen-induced AHR and reactivity to 
methacholine.
27 In contrast, C3H/HeJ and DBA/2 mice are 
comparatively resistant to the development of allergen-in-
duced AHR.
27,28 Among the strains, BALB/c and C57BL/6 mice 
are the most widely used due to their well-characterized im-
munological responses. BALB/c mice typically mount Th2-
dominated immune responses, and the induction of parame-
ters of allergic responses such as allergen-specific IgE, AHR, 
and eosinophilic airway inflammation are robust. Conversely, 
C57BL/6 mice exhibit Th1-dominated immune responses, and 
have limitations in the development of allergic airway respons-
es compared with BALB/c mice especially in the development 
of allergen-specific IgE responses and airway responsiveness to 
inhaled methacholine. Surprisingly, in response to allergen 
challenge, for example to ovalbumin (OVA), they do develop a 
robust BAL eosinophilic response,
29 and in the tissue tend to 
accumulate more eosinophils in the parenchyma than around 
the airways, in contrast to BALB/c mice where eosinophils ac-
cumulate around the airways.
30 However, C57BL/6 mice are 
widely used as strains of most gene-manipulated mice are on 
this background. 
The availability of genetically-manipulated animals enables 
the investigation of the genetic influence on susceptibility to 
sensitization and development of allergic airway inflammation. 
Targeting of specific genes has served to identify pathways 
uniquely involved in disease development and progression. 
Thus, the contribution of a given molecule in disease develop-
ment has been identified through the use of gene-deletion or 
Table 2. Advantages and disadvantages of non-invasive and invasive airway function measurements
Methods Advantage Disadvantage
Non-invasive Fast and easy Interference from upper airways
Use aerosolized stimulants Prone to artifacts (movement)
Repeated and long term measurements in the same animal Breathing patterns only but not physiological values
Normal breathing pattern with no need for anesthesia or tracheal instrumentation No direct assessment of pulmonary mechanics
Invasive Reproducible and precise Need for tracheostomy
Avoid changes in the upper airways Need for anesthesia
Opportunity for bronchoalveolar lavage fluid collection Need for mechanical ventilation
Based on physiological principles No repeated measurements
Intact anatomical relationship in the lung Expertise Allergy Asthma Immunol Res. 2009 October;1(1):10-18.  doi: 10.4168/aair.2009.1.1.10
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knockout mice, which are genetically-manipulated to produce 
a defective or non-functional version of a gene-related product 
or to overexpress a gene product. However, such studies require 
careful scrutiny as the effects are developmental in origin, and 
genetic manipulation circumvents naturally occurring regula-
tory or control mechanisms or may be compensated by un-
known pathways. To circumvent some of these limitations, 
technologies using conditional knockout approaches have 
been developed in which the developmental concerns are by-
passed and where the target gene can be directly manipulated 
at defined times. Transgenic mice have also been used to ex-
amine the impact of overexpression of a gene of interest on the 
course of disease development. The transgenic genes can dis-
rupt the expression of other genes which can be induced by the 
random insertion of target genes. Therefore, once animals ex-
pressing the transgene have been made, it is important to con-
firm that insertion did not disrupt the expression of other 
genes.
ALLERGENS 
A number of allergens have been used in animal models of 
asthma. In most studies, OVA has been used to sensitize and 
challenge host animals. OVA is relatively inexpensive, can be 
highly purified, the immunodominant epitopes have been 
well-characterized, and recombinant peptides have been gen-
erated. Purified OVA can be prepared without protease or en-
dotoxin which is abundant in other allergens.
31 In most strains, 
repeated inhalation of OVA may induce the development of 
tolerance, rather than sustained allergic airway responses. For 
sensitization, OVA is usually combined with adjuvant and in-
jected to prime for allergic airway inflammation.
32 Following 
sensitization, a series of inhaled or intranasal challenges are 
administered to elicit responses. OVA-induced allergic airway 
models may not represent the same conditions experienced by 
asthmatics where allergen exposure may be more frequent and 
for much longer periods of time. Although allergens represent 
an important component of allergy induction, other factors 
such as lipopolysaccharides (LPS, endotoxin) may contribute 
as they are ubiquitous in the environment. Small amounts of 
LPS usually contaminate preparations of OVA and are likely es-
sential for sensitization in mice. In one study sensitization to 
OVA via the intranasal route was shown to be dependent on 
LPS in the preparation but this requirement was bypassed 
when sensitization systemically was combined with adjuvant.
33 
LPS-free OVA may induce tolerance and prevent development 
of allergic airway inflammation or AHR.
34 Extracts or purified 
proteins derived from potent human allergens including house 
dust mite (HDM), cockroach, ragweed, or fungi have been in-
creasingly used as allergens in mice and other species.
35-41 Re-
peated administration of a combination of three allergens may 
avoid the development of tolerance.
42 These allergens induce 
asthma attacks in humans and some studies have demonstrat-
ed their potency to induce chronic airway inflammation and 
tissue remodeling in mice. It is also apparent that even follow-
ing the same protocols, different allergens in different strains 
elicit quite different responses.
43
EXPERIMENTAL PROTOCOLS 
At the present time there is no standardized experimental 
protocol; most laboratories have developed their own protocols 
either with major or minor modifications. Simple reliance on a 
single model poses many problems when data are analyzed. 
Similarly, because of the number of models used, it is very diffi-
cult to compare results from different studies. As the experi-
mental approach is so important to the outcomes, it is an area 
ripe for consolidation and standardization. Our approach has 
been to investigate several different models in order to fully ex-
plore the complexity of the outcomes under different condi-
tions. 
Primary allergen challenge model 
Mice do not spontaneously develop AHR or allergic airway 
inflammation. Therefore, to investigate the development of 
lung inflammatory responses, an artificial asthma-like reaction 
has to be induced in the airways. Primary allergen challenge 
models have been widely used to elucidate the mechanisms 
underlying the allergen-induced immunologic and inflamma-
tory responses in the airways. Although many different sensiti-
zation and challenge protocols exist, the basic model is shared, 
with a sensitization phase and a challenge phase. Single or 
multiple systemic injections of allergen with or without adju-
vant are used to induce sensitization. Adjuvants such as alumi-
num hydroxide are known to promote the development of Th2-
type responses. Adjuvant-free protocols are also effective, but 
these usually require a greater number of exposures to achieve 
the proper sensitization, and even then, elicit less robust re-
sponses on allergen challenge.
44 In the challenge phase, gener-
ally 2-4 weeks after completion of sensitization, allergens are 
administered in a nebulized form or administered by deposi-
tion through the intratracheal or intranasal route. The primary 
allergen challenge models are relatively short-term and show 
high reproducibility. The responses elicited include elevated 
levels of allergen-specific IgE, eosinophilic airway inflamma-
tion, and AHR. However, due to the short-term nature of pri-
mary allergen challenge models, one of the key features ob-
served in asthmatics, airway remodeling, is minimal and many 
of the other parameters (AHR, eosinophilic inflammation) are 
transient. Airway inflammation and AHR have been shown to 
resolve within a few weeks after the final allergen inhalation.
45 It 
is this model which has been most used in pre-clinical studies, 
as a prelude to a clinical trial. This model has several limitations 
and results are often overinterpreted to represent asthma. As a Allergy Asthma Immunol Res. 2009 October;1(1):10-18.  doi: 10.4168/aair.2009.1.1.10
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result, it is not surprising that most extensions to asthma have 
failed in the clinic. This model is not a model of asthma, the hu-
man disease.
Secondary allergen challenge models
The responses to primary allergen challenges, including AHR, 
eosinophilic inflammation, and goblet cell metaplasia can be 
induced by the first exposures to allergen in sensitized mice. 
Often described as an acute exposure model, this contrasts 
with asthma where allergen exposure is repeated and chronic. 
Therefore, secondary allergen challenge models were devel-
oped to more closely mimic the conditions of allergic asthma 
with allergen re-challenge after animals received sensitization 
and primary allergen challenge. Animals are exposed to sec-
ondary allergen challenge 2-6 weeks after primary allergen 
challenge when airway eosinophilia and AHR have resolved 
and returned to baseline levels. A single provocative or second-
ary allergen challenge elicits airway eosinophilia and neutro-
philia, lymphocyte accumulation, and altered airway function. 
The advantage of this protocol is the ability to monitor the ki-
netics of inflammatory parameters induced by a single allergen 
challenge and the effect of treatment. This approach revealed 
that the requirements for some of the responses to secondary 
challenge differed from those suggested to be critical in the re-
sponse to primary allergen challenge.
46,47
Chronic allergen challenge models 
Asthma is defined as a chronic inflammatory disorder of the 
airways with structural changes in the airways including sub-
epithelial fibrosis, goblet cell metaplasia, smooth muscle thick-
ening, and increased vascularity.
48,49 Although primary and sec-
ondary allergen challenge animal models elucidate many 
aspects of human asthma, there are limitations to these models 
when compared to asthmatics. Several laboratories have inves-
tigated chronic allergen challenge models in mice to more 
closely mimic the human disease. Various models have been 
developed by increasing the number of allergen exposures over 
many weeks. OVA as well as other allergens such as HDM ex-
tract and/or grass pollen have been used.
50-53 In many of these 
studies long-term challenge leads to the development of toler-
ance and progressive decreases in AHR and airway eosinophil-
ia.
54 The induction of tolerance may be dependent on the strain 
of mouse used and the nature and route of allergen administra-
tion.
45,55 Chronic models have been shown to reproduce some 
of the hallmarks of asthma such as goblet cell metaplasia, epi-
thelial hypertrophy, subepithelial fibrosis and limited smooth 
muscle hyperplasia. Regrettably, chronic allergen challenge 
models have had limited use in the preclinical evaluation of 
novel therapeutic agents where compounds can be tested on a 
background of established allergic airway disease. Certain 
atypical features are observed in these chronic allergen chal-
lenge models that are not observed in humans, for example, in-
flammation is not restricted to the conducting airways in the 
mouse, whereas it is restricted in humans. In addition, there are 
few mast cells in the airway walls or epithelium of mice.
56,57 De-
spite these concerns, development of a standardized chronic 
model in mice is important as many of the clinical studies were 
initiated based on outcomes in primary allergen challenge 
models. 
Exclusive airway exposure to allergen and passive sensitization 
to assess lung allergic responses
These were some of the first models which assessed airway 
function in mice.
58 Briefly, sensitization and induction of AHR 
were achieved by airway allergen challenge exclusively for 10 
days or following passive sensitization with allergen-specific 
IgE followed by two days of airway allergen challenge.
59 In both 
cases there was no systemic sensitization. This is similar to the 
natural mode of sensitization to airborne allergens in asthmat-
ics. Since no adjuvants are used, IgE production and airway in-
flammatory responses are somewhat lower than observed fol-
lowing systemic sensitization.
60 Importantly, these models, 
unlike those incorporating systemic sensitization, are both IgE 
and mast cell-dependent.
61 
Dendritic cell-dependent models
In mice, the sensitization phase can be bypassed using adop-
tive transfer of allergen-primed dendritic cells (DCs) which are 
efficient antigen-presenting cells (APC).
62 Bone marrow-de-
rived DCs (BMDCs) can be differentiated and expanded from 
precursors in vitro in the presence of GM-CSF (with or without 
IL-4). The bone marrow-derived DCs are primed to allergen 
and initiate naive T-cell differentiation in vivo when they are 
adoptively transferred into mice that are then exposed to aller-
gen via the airways on three consecutive days.
63 When allergen-
primed DCs are administered directly into the airways of mice 
followed by exposure to allergen, an asthma-like phenotype is 
induced.
63,64 Such experiments have highlighted the impor-
tance of DCs in the initiation of allergic airway disease and 
identify DCs as therapeutic targets.
65 BMDCs are different than 
the naturally occurring lung DCs, the myeloid and plasmacytoid 
subsets, that differentially regulate lung allergic responses.
66
MONITORING OUTCOMES IN DIFFERENT MODELS
The physiologic hallmark of asthma is reversible airway ob-
struction, accompanied by airway hyperreactivity to broncho-
constrictors and non-specific stimuli. In humans, allergen chal-
lenge can induce immediate- and/or late-phase responses. 
Although assessments of early allergic responses are feasible in 
mouse models,
67 most studies assess changes in airway respon-
siveness to non-specific agonists such as methacholine (in-
haled or administered intravenously) or acetylcholine (admin-
istered intravenously) after allergen challenge(s). Allergen Allergy Asthma Immunol Res. 2009 October;1(1):10-18.  doi: 10.4168/aair.2009.1.1.10
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exposure in sensitized mice results in significant increases in 
airway responsiveness to cholinergic agonists when compared 
to the non-exposed controls. Several different methods are 
used to measure airway responsiveness in mice following aller-
gen exposure (Table 2).
Non-invasive airway function measurements 
Non-invasive approaches have been used to assess airway 
function. Spontaneously breathing, non-anesthetized mice are 
placed in the main chamber of a whole body plethysmograph. 
The response of the airways to inhaled methacholine is mea-
sured and compared to the response to a control inhalant 
(aerosolized saline). Airway function is expressed as the calcu-
lated parameter “enhanced pause” (Penh). Briefly, Penh is an 
empirical parameter that reflects changes in the box flow wave-
form between inspiration and expiration and combines these 
results with the early and late expiratory box flow (Pause). Non-
invasive measurements such as this have several potential ad-
vantages compared to invasive methods as they are technically 
less demanding and can be used to monitor AHR over time in 
the same animal. When carried out in experienced hands, the 
results correlate with those of the invasive methods.
68 Although 
faster and somewhat easier, this approach requires careful cali-
bration, may be better suited to responsive strains such as 
BALB/c mice, and the results can be affected by any impinge-
ment on nasal airflow. The validity of this method has been 
questioned and in fact has engendered a great deal of debate 
because it is difficult to exclude the influence of the upper air-
ways, and Penh is based on breathing patterns but not physio-
logical values.
69 Investigators have used this technique for 
screening large numbers of compounds and defining genetic 
control of airway responsiveness, often in concert with invasive 
methods to confirm the results.
70 
Invasive airway function measurements 
Invasive methods more directly measure pulmonary me-
chanics in mice and represent the current gold standard in air-
way physiology. AHR can be assessed more directly by measur-
ing changes in respiratory (lung) resistance (RL) and dynamic 
compliance (Cdyn) in response to increasing concentrations of 
inhaled or intravenously administered methacholine or acetyl-
choline. RL is the sum of airway and tissue resistance, which is 
fairly comparable at normal breathing rates.
71 Cdyn is calculated 
by relating the volume changes to the concomitant elastic recoil 
pressure changes between end inspiration and end expiration. 
The advantages of the invasive measurements are the precise 
assessments of transient changes in pulmonary mechanics. 
The insertion of a tracheal tube avoids changes secondary to 
the upper airways and provides the opportunity for extracting 
bronchoalveolar lavage fluid after lung function measurements 
are performed. The disadvantages include the need for surgical 
tracheostomy, thus precluding repeated measurements, the 
needs for anesthesia, mechanical ventilation, and expertise in 
handling. 
 
Electrical field stimulation (EFS)
Although the in vivo response to inhaled methacholine is the 
most widely used method of assessing AHR in mice, it was ini-
tially limited in the mouse due to the difficulty of delivering an 
aerosol to the airways. To determine the effects of EFS, tracheal 
smooth muscle segments (TSM) are isolated after allergen 
challenge and placed in baths with supporting longitudinally 
stainless steel wire. Repetitive currents are applied at increasing 
frequencies to define the frequency that elicits a 50% maximal 
contraction (ES50). Following allergen challenge, the reduction 
in ES50 was shown to reflect M2 receptor dysfunction and the 
increase in acetylcholine release.
72 These alterations may be in-
duced by eosinophilic major basic protein.
73 EFS has been used 
to investigate mast cell-dependent increases in airway respon-
siveness and neural airway control.
74
SUMMARY
For the last several decades, various animal models have been 
studied and have contributed to the further understanding of 
the mechanisms underlying allergic airway disease. There are 
very few pathologic features not shared in mouse models and 
human asthma. The advances in technology, availability of new 
equipment, introduction of potent reagents and genetically-
manipulated mice continue to provide unique opportunities to 
explore the pathogenesis of allergen-induced airway inflam-
mation and airway dysfunction in ways not available to clinical 
research in patients. What is lacking is development of guide-
lines to establish more uniformity in approach and outcomes 
so that different studies are more easily compared.
Nonetheless, the mouse like other species has several limita-
tions including the facts that they do not have spontaneous 
symptoms or long-lasting bronchoconstriction as seen in asth-
matics, their lungs are more fully developed at birth so environ-
mental influences have different effects, the structure of mouse 
lungs is very different than in humans, mice are obligate nasal 
breathers, and chronic asthma models and evidence for re-
modeling, e.g., smooth muscle hypertrophy is limited. Al-
though no mouse model fully mimics the full range of clinical 
manifestations of asthma, many do reproduce a collection of 
the features that characterize its most common forms and they 
yield a basic core of phenotypic consequences.
In summary, mouse models cannot be considered a surrogate 
for human asthma or a panacea for difficulties encountered in 
human study design and outcomes, but rather should be seen 
as an important opportunity to generate and test hypotheses in 
simple, controlled systems. The clinical relevance of the find-
ings in mice or any other species can only be determined in hu-
man studies.Allergy Asthma Immunol Res. 2009 October;1(1):10-18.  doi: 10.4168/aair.2009.1.1.10
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